Inhibitor Therapeutics, Inc. is a pharmaceutical development company that is focused on developing and ultimately commercializing innovative therapeutics for patients with certain cancers and certain non-cancerous proliferation disorders. We have also explored and expect to continue to explore acquiring or licensing other innovative preclinical and clinical stage therapeutics addressing unmet needs and orphan indications beyond cancer. While the Company is not presently conducting research and development activities with respect to its currently in-licensed technologies and its own intellectual property as a result of recently settled litigations involving the Company, the Company expects to continue to explore acquiring or licensing innovative preclinical and clinical stage therapeutics following the recent litigation settlement.
Company profile
Ticker
INTI
Exchange
Website
CEO
Nicholas Virca
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
COMMONWEALTH BIOTECHNOLOGIES INC, HedgePath Pharmaceuticals, Inc.
SEC CIK
Corporate docs
IRS number
541641133
INTI stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
29 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Departure of Directors or Certain Officers
31 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
8-K
Entry into a Material Definitive Agreement
19 Dec 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
In the Court of Chancery of the State of Delaware
15 Sep 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
8-K
Departure of Directors or Certain Officers
3 Jun 22
Latest ownership filings
4
RONALD E OSMAN
29 Aug 23
3
RONALD E OSMAN
29 Aug 23
SC 13D
Black Robe Capital LLC
23 May 23
SC 13G
TPB 2012 LLC
23 May 23
3
James Joseph Donovan III
22 May 23
SC 13G
Ronald E Osman Irrevocable Trust III
18 May 23
4
JAMES A MCNULTY
17 May 23
3
JAMES A MCNULTY
17 May 23
4
Michelle Yanez
17 May 23
3
SAMUEL P SEARS JR
22 Dec 22
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 10.10 mm | 10.10 mm | 10.10 mm | 10.10 mm | 10.10 mm | 10.10 mm |
| Cash burn (monthly) | 227.54 k | (no burn) | 247.49 k | 155.48 k | 227.54 k | (no burn) |
| Cash used (since last report) | 651.20 k | n/a | 708.30 k | 444.99 k | 651.20 k | n/a |
| Cash remaining | 9.45 mm | n/a | 9.39 mm | 9.66 mm | 9.45 mm | n/a |
| Runway (months of cash) | 41.5 | n/a | 37.9 | 62.1 | 41.5 | n/a |
Institutional ownership, Q1 2023
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 0.00 |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 11 Aug 23 | Osman Ronald E | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 23,514,985 |
| 5 May 23 | Mcnulty James A | Common Stock | Other | Acquire J | Yes | No | 0 | 20,101,057 | 0.00 | 26,101,057 |
| 5 May 23 | Mcnulty James A | Common Stock | Other | Acquire J | No | No | 0 | 398,135 | 0.00 | 946,135 |
| 5 May 23 | Mcnulty James A | Common Stock | Other | Dispose J | Yes | No | 0 | 79,627,069 | 0.00 | 0 |
| 5 May 23 | Michelle Yanez | Common Stock | Other | Acquire J | No | No | 0 | 796,271 | 0.00 | 800,673 |